ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1654374
This article is part of the Research TopicUnleashing Immunity against Cancer: New Horizons in ImmunotherapyView all 3 articles
SLAMF7 (CD319) enhances cytotoxic T-cell differentiation and sensitizes CD8⁺ T cells to immune checkpoint blockade
Provisionally accepted- 1Department of Experimental Pediatrics, Faculty of Medicine, University Hospital Magdeburg, Magdeburg, Germany
- 2Institute for Transfusion Medicine Dessau, Red Cross Blood Transfusion Service NSTOB, Dessau-Roßlau, Germany
- 3Department of Otorhinolaryngology, Head and Neck Surgery, Faculty of Medicine, University Hospital Magdeburg, Magdeburg, Germany
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Tumors frequently evade immune destruction by impairing cytotoxic CD8 + T-cell responses, highlighting the need for strategies that restore T-cell functionality. Here, we identify SLAMF7 (CD319) as a key enhancer of human CD8 + T-cell responses against tumors. SLAMF7 expression is induced by pro-inflammatory signals such as IL-12 and CD28 co-stimulation. Agonistic SLAMF7 signaling, in synergy with TCR activation, is able to strongly induce T-cell activation and clonal expansion, a finding consistently observed in CD8 + T cells from healthy adults as well as derived from blood and tumor-draining lymph nodes of patients with head and neck squamous cell carcinoma (HNSCC). Moreover it drives a distinct differentiation programme characterized by elevated expression of key transcription factors Eomes and T-bet, leading to increased production of effector molecules such as Interferon , Granzyme B and Perforin. In contrast to CD28 costimulation, SLAMF7 activation also promotes serial killing potential via BTLA induction. In antigen-specific human models, SLAMF7 activation boosts CD8 + T-cell responses against the tumor-associated antigen NY-ESO-1, a key target in several cancers including HNSCC. Moreover, combining SLAMF7 activation with PD-1/PD-L1 immune checkpoint blockade synergistically enhances cytokine release and cytotoxic potential, highlighting its potential to overcome immunosuppression and reinvigorate antitumor immunity.
Keywords: SLAMF family, T-cell differentiation, Cytotoxicity, costimulation, Cancer, Immunotherapy, tumor rejection, Head and neck squamous cell carcinoma (HNSCC)
Received: 26 Jun 2025; Accepted: 31 Jul 2025.
Copyright: © 2025 Sander, Han, Fickenscher, Schmidt, Kroll, Vosikova, Durisin, Lingel and Brunner-Weinzierl. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Monika C. Brunner-Weinzierl, Department of Experimental Pediatrics, Faculty of Medicine, University Hospital Magdeburg, Magdeburg, Germany
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.